

Primary Immunodeficiency Diseases Market - 2023-2031

<https://marketpublishers.com/r/P79780C6C656EN.html>

Date: November 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: P79780C6C656EN

Abstracts

The Primary Immunodeficiency Diseases Market was valued at US\$ 7.3 billion in 2023 and is anticipated to reach US\$ 13.0 billion by 2031, at a CAGR of 0.076 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Primary Immunodeficiency Diseases Market.

This report delivers a comprehensive overview of the Primary Immunodeficiency Diseases Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Primary Immunodeficiency Diseases Market. The Primary Immunodeficiency Diseases Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Primary Immunodeficiency Diseases Market Scope:

By Disease Type

Antibody Deficiency

Cellular Immunodeficiency

Innate Immune Disorders

By Treatment

Immunoglobulin (Ig) Replacement Therapy

Hematopoietic Stem Cell Therapy

Gene Therapy

Others

By End-User

Hospitals

Specialty Clinics

Academic and research centers

Others

Key Players

Abbott Laboratories

AstraZeneca

Pfizer

Baxter International Inc.

Bayer

Bristol Myers Squibb

Eli Lilly

Biotest AG

Grifols

CSL Behring

Major Highlights

This report delivers a comprehensive overview of the Primary Immunodeficiency Diseases Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Primary Immunodeficiency Diseases Market. The Primary Immunodeficiency Diseases Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Disease Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Prevalence of Primary Immunodeficiency Diseases
 - 4.1.1.2. Advancements in the fields of Immunology and Diagnostics
 - 4.1.2. 4.1.2 Restraints
 - 4.1.3. 4.1.2.1 High Cost Associated with the Treatment
 - 4.1.4. 4.1.2.2. Lack of awareness among people
 - 4.1.5. 4.1.3 Opportunity
 - 4.1.6. 4.1.4 Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
- 5.6. PESTEL Analysis
- 5.7. Patent Analysis
- 5.8. SWOT Analysis

6. BY DISEASE TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

6.1.2. Market Attractiveness Index, By Disease Type

6.2. Antibody Deficiency *

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Cellular Immunodeficiency

6.4. Innate Immune Disorders

7. BY TREATMENT

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

7.1.2. Market Attractiveness Index, By Application

7.2. Immunoglobulin (Ig) Replacement Therapy*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Hematopoietic Stem Cell Therapy

7.4. Gene Therapy

7.5. Others

8. BY END-USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.1.2. Market Attractiveness Index, By End-User

8.2. Hospitals*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Specialty Clinics

8.4. Academic and research centers

8.5. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
 - 9.2.1. Introduction
 - 9.2.2. Key Region-Specific Dynamics
 - 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.2.6.1. The U.S.
 - 9.2.6.2. Canada
 - 9.2.6.3. Mexico
- 9.3. Europe
 - 9.3.1. Introduction
 - 9.3.2. Key Region-Specific Dynamics
 - 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.3.6.1. Germany
 - 9.3.6.2. UK
 - 9.3.6.3. France
 - 9.3.6.4. Italy
 - 9.3.6.5. Spain
 - 9.3.6.6. Rest of Europe
- 9.4. South America
 - 9.4.1. Introduction
 - 9.4.2. Key Region-Specific Dynamics
 - 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.4.6.1. Brazil
 - 9.4.6.2. Argentina
 - 9.4.6.3. Rest of South America
- 9.5. Asia-Pacific
 - 9.5.1. Introduction
 - 9.5.2. Key Region-Specific Dynamics
 - 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Abbott Laboratories *

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Financial Overview

11.1.4. Key Developments

11.2. AstraZeneca

11.3. Pfizer

11.4. Baxter International Inc.

11.5. Bayer

11.6. Bristol Myers Squibb

11.7. Eli Lilly

11.8. Biotest AG

11.9. Grifols

11.10. CSL Behring (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Primary Immunodeficiency Diseases Market - 2023-2031

Product link: <https://marketpublishers.com/r/P79780C6C656EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P79780C6C656EN.html>